drugset / Trial / NCT03285321
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Phase 2
Completed
105 enrolled
Greg Durm, MD
Big Ten Cancer Research Consortium · collabBristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.
Timeline
- Start
- 2017-09-15
- Primary completion
- 2023-10-13
- Completion
- 2024-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |